Still mulling this over....

I guess the Mother-of-All Excess Bids got everyone a little distracted, and not necessarily focused on the FDA LOA "enhancements"

(...Wow, does that sound familiar......spring/summer of 2007 with a different distraction issue...)

Anyway, it's clear there are a couple of bennies in here from a "tactical" standpoint for those the guys who have already voluntarily made a self-assessment and agreed to go to HKG under the current FDA LOA, but I have yet to hear anything on the "strategic" benefits of accepting this FDA LOA.

How does agreeing to another FDA LOA, that is lacking in so many areas, fit into our strategic plan for overall FDA improvements?

How does adding very small improvements to just barely fill the FDAs increase our strategic leverage now and/or in the future?

How does continuing to let the company design a set of FDA benefits that is only acceptable to a very small segment of our overall pilot group benefit the overall pilot group, when it has been repeatedly communicated by the company (and the current state of the US economy) that these FDAs are the "growth areas" for our company?

Is the vast majority of our pilot group going to once again, fall into the trap that the outcome of this FDA LOA vote simply doesn't affect them?

Are these the final conditions we find sufficient to bid/open CDG with the A300 in 12-18 months, and HKG with the MD11 in the "near future", as folks are being told in RGS?

Are the grave concerns that the company will "outsource" the FDA flying, if we don't get on board and grab it, valid when contemplating this LOA vote?

I posted a couple of these questions a few weeks back, but got little to no response....perhaps we've all been distracted by calculating our paycuts and reviewing our household budgets.

...hopefully not too distracted that we miss an opportunity to start viewing the FDAs "strategically".

If not now.....when?